Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment - Full Text View

Purpose

The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.

Condition	Intervention	Phase
Diabetes Mellitus	Drug: Lantus (insulin glargine [rDNA origin] injection) Drug: Metformin Drug: Glyburide Drug: Thiazolidinedione	Phase IV

MedlinePlus related topics:

Diabetes

ChemIDplus related topics:

Insulin Insulin glargine Glyburide Metformin Metformin hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Substituting Lantus®(Insulin Glargine[rDNAorigin]Inj) for a Thiazolidinedione vs. a 3rd Oral Agent as Add-on Therapy in Patients Failing a Thiazolidinedione & Sulfonylurea or Metformin Combination

Further study details as provided by Sanofi-Aventis:

Primary Outcome Measures:

To determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy [ Time Frame: During the Study Conduct ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Occurrence of hypoglycemia [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
Change in fasting plasma glucose [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
Percentage of patients achieving HbA1C less than or equal to 7% [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
Time to glycemic control [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
Change in body weight [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]
Change in serum lipid profile [ Time Frame: During the study conduct ] [ Designated as safety issue: No ]

Estimated Enrollment:	240
Study Start Date:	November 2001
Study Completion Date:	December 2004
Primary Completion Date:	November 2004 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 79 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients between 18 - 79 years of age
With diagnosed type 2 diabetes for at least a year treated with stable doses of two oral antidiabetic drugs of which one is either Avandia or Actos for at least three months.

Exclusion Criteria:

Major cardiovascular events

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00046462

Locations


United States, New Jersey
	Aventis
	Bridgewater, New Jersey, United States, 08807

Sponsors and Collaborators

Sanofi-Aventis

Investigators


Study Director:	Doug Green	Sanofi-Aventis

More Information

Responsible Party:	sanofi-aventis ( Medical Affairs Study Director )
Study ID Numbers:	HOE901/4022
First Received:	September 30, 2002
Last Updated:	July 28, 2008
ClinicalTrials.gov Identifier:	NCT00046462
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Glyburide

Metabolic Diseases

Metformin

Glargine

Diabetes Mellitus

2,4-thiazolidinedione

Endocrine System Diseases

Endocrinopathy

Metabolic disorder

Glucose Metabolism Disorders

Insulin

Additional relevant MeSH terms:

Hypoglycemic Agents

Physiological Effects of Drugs

Pharmacologic Actions

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	Sanofi-Aventis
Information provided by:	Sanofi-Aventis
ClinicalTrials.gov Identifier:	NCT00046462